The size of the legionella testing market will power at a rate of 8% in the years to come, reaching USD 554 million by 2030. The major factors which are powering the industry are the growing occurrence of Pontiac fever, Legionnaire’s ailment, and pneumonia.
The industry will grow significantly because of the growth in the elderly populace, as older people are susceptible more than the young people, to infection by this bacterium because of their reduced immunity, along with the fact that they have hypertension, diabetes, chronic kidney disease, and chronic obstructive pulmonary disease.
The PCR category dominated the industry in the past. PCR is the common process put to use for detection of legionella bacteria as it demonstrates the outcomes in one day and is extremely precise, explicit, and sensitive.
North America legionella testing market had the largest share, of 44%, in 2022, as a result of the growing count of patients with legionella infection and the expansion of the healthcare system. An estimated 8,000–18,000 individuals in the U.S. are admitted to hospitals every year with Legionnaire’s disease.
Europe follows North America, and it will power at a rate of 8.1% by the end of this decade, as a result of the approvals/authorization of testing kits and’ awareness programs of the governments, both of which drive the requirement for the related products.
Due to the increasing occurrence of pneumonia and fever all over the world, the demand for legionella testing will continue to increase in the years to come.